ATE339690T1 - Verfahren zum screening von verbindungen auf aktivität bei der behandlung einer mit osteoklasten zusammenhängenden knochenerkrankung - Google Patents

Verfahren zum screening von verbindungen auf aktivität bei der behandlung einer mit osteoklasten zusammenhängenden knochenerkrankung

Info

Publication number
ATE339690T1
ATE339690T1 AT02715378T AT02715378T ATE339690T1 AT E339690 T1 ATE339690 T1 AT E339690T1 AT 02715378 T AT02715378 T AT 02715378T AT 02715378 T AT02715378 T AT 02715378T AT E339690 T1 ATE339690 T1 AT E339690T1
Authority
AT
Austria
Prior art keywords
treatment
osteoclast
activity
related bone
bone disease
Prior art date
Application number
AT02715378T
Other languages
English (en)
Inventor
Anne Marie Heegaard
Michael Thyrring Engsig
Lars Siim Madsen
Bo Skaaning Jensen
Palle Christophersen
Martin Stahlhut
Morten Asser Karsdal
Original Assignee
Pharmos Bioscience As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmos Bioscience As filed Critical Pharmos Bioscience As
Application granted granted Critical
Publication of ATE339690T1 publication Critical patent/ATE339690T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT02715378T 2001-01-23 2002-01-17 Verfahren zum screening von verbindungen auf aktivität bei der behandlung einer mit osteoklasten zusammenhängenden knochenerkrankung ATE339690T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200100118 2001-01-23
US26587401P 2001-02-05 2001-02-05

Publications (1)

Publication Number Publication Date
ATE339690T1 true ATE339690T1 (de) 2006-10-15

Family

ID=26068950

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02715378T ATE339690T1 (de) 2001-01-23 2002-01-17 Verfahren zum screening von verbindungen auf aktivität bei der behandlung einer mit osteoklasten zusammenhängenden knochenerkrankung

Country Status (8)

Country Link
US (1) US20040224881A1 (de)
EP (1) EP1360504B1 (de)
JP (1) JP2004522441A (de)
AT (1) ATE339690T1 (de)
AU (1) AU2002224758A1 (de)
DE (1) DE60214673T2 (de)
DK (1) DK1360504T3 (de)
WO (1) WO2002059356A2 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003062821A1 (en) * 2002-01-23 2003-07-31 Bristol-Myers Squibb Company Modulators of the clc-7 chloride channel and methods for their identification and use in the treatment and prevention of osteoporosis and related disease states
GB0227243D0 (en) * 2002-11-21 2002-12-31 Univ Aberdeen Genetic markers for bone mass
GB0525898D0 (en) * 2005-12-20 2006-02-01 Pharmo Bioscience As Screening compounds for activity in modulating chloride ion transport
EP2420830B1 (de) 2010-08-16 2016-11-16 Forschungsverbund Berlin e.V. Chloridtransporter ClC-7 und zellbasiertes Screening-Verfahren
JP6261048B2 (ja) * 2012-12-05 2018-01-17 国立大学法人 新潟大学 破骨細胞が関与する疾患の予防又は治療剤

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2342626A1 (en) * 1998-10-22 2000-05-04 Neurosearch A/S Substituted phenyl derivatives, their preparation and use
US7399599B2 (en) * 2000-07-10 2008-07-15 Vertex Pharmaceuticals (San Diego) Llc Ion channel assay methods
DE10102977A1 (de) * 2001-01-23 2002-08-01 Thomas Jentsch Testsystem zur Entwicklung von Therapeutika, insbesondere von Wirkstoffen zur Behandlung von Osteoporose

Also Published As

Publication number Publication date
DE60214673T2 (de) 2007-09-13
EP1360504A2 (de) 2003-11-12
DE60214673D1 (de) 2006-10-26
JP2004522441A (ja) 2004-07-29
AU2002224758A1 (en) 2002-08-06
US20040224881A1 (en) 2004-11-11
WO2002059356A3 (en) 2003-05-01
DK1360504T3 (da) 2007-01-29
EP1360504B1 (de) 2006-09-13
WO2002059356A2 (en) 2002-08-01

Similar Documents

Publication Publication Date Title
ATE414089T1 (de) Verwendung von rapamycin und dessen derivaten zur behandlung von knochenverlust
ATE429645T1 (de) Verwendung von eph-rezeptor-inhibitoren zur behandlung neurodegenerativer krankheiten
NO20052928L (no) Nye kjemiske forbindelser
DE60034871D1 (de) Verfahren und zusammensetzungen zur prevention oder behandlung von krebs und von krebs assoziertem knochenverlust
DE602004020657D1 (de) Neue verwendung von peptidverbindungen zur behandlung ovn zentralen neuropathischen schmerzen
ATE331527T1 (de) Verfahren zur behandlung von brustdrüsenerkrankungen
DE602004003952D1 (de) Substituierte tetrahydrobenzothienopyrimidinamine verbindungen geeignet zur behandlung von hyper-proliferative disorders
ATE422498T1 (de) Tetrahydro-pyrazinoä1,2-aüindole für die behandlung von krankheiten des zentralnervensystems
DE602004019897D1 (de) Verfahren zur racematspaltung von 2,4-diamino-3,6-dihydro-1,3,5-triazinen, die sich zur behandlung vkrankungen eignen
DE60223688D1 (de) Verfahren zur behandlung von multiplem myelom
DE60330146D1 (de) Verfahren zur reinigung von fibrinogen
DE60122673D1 (de) Methoden zur diagnose und behandlung von herzkrankheiten
EP1684735A4 (de) Verbindungen und verfahren zur behandlung und prävention von belastungsinduzierten herzarrhythmien
DE60217479D1 (de) Verfahren zur kontinuierlichen behandlung von wasser aus zahnärztlichen geräten
EA200601220A1 (ru) Анти-trkc антитела-агонисты и способы их применения
DE60326248D1 (de) Verbindungen, zusammensetzungen und verfahren zur behandlung von zellulären proliferativen erkrankungen
EP1868437A4 (de) Verfahren zur behandlung oder verhinderung von knochenabbau oder osteoporose
ATE339690T1 (de) Verfahren zum screening von verbindungen auf aktivität bei der behandlung einer mit osteoklasten zusammenhängenden knochenerkrankung
ATE359816T1 (de) Verfahren zur prävention und behandlung von infektionen mit dem flavivirus bei tieren
ATE346597T1 (de) Carbamate verbindungen zur behandlung oder verhutung von psychotischen krankheiten
DE60214388D1 (de) Verbindungen, bei denen es sich um wirksame inhibitoren des na+/ca2+ austauschmechanismus handelt und die sich zur behandlung von arrhythmien eignen
DE60223707D1 (de) Calcium-l-threonat zur behandlung von knochenfrakturen
ATE361071T1 (de) Verwendung von irbesartan zur vorbeugung oder behandlung pulmonaler hypertonie
DE60142786D1 (de) Zusammensetzungen und methoden zur behandlung von candidosen
DE60213365D1 (de) Verwendung von mglur5 antagonisten zur behandlung von pruritischen zuständen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties